Nursing Pharmacology: Antiviral Drugs

Previous Page Page Forward
Section Table of Contents
Site Table of Contents

Protease Inhibitors

Previous Page Page Forward
Section Table of Contents
Site Table of Contents

References

  1. Wang F Kieff E Medical Viriology, Chapter 177 Section 11:  Viral Diseases:  General Considerations (in Harrison's Principles of Internal Medicine, 18th edition, Longo DF Fauci AS Kasper DL Hauser SL Jameson JL Loscalzo J, eds) McGraw-Hill, New York, 2012, pp 1432-1433.

  2. Flexner C Chapter 59.  Antiretroviral Agents and Treatment of HIV Infection (in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12 e, Brunton LL Chabner BA Knollmann BC, eds) The McGraw-Hill Companies, Inc, 2011.

  3. Safrin S Chapter 49:  Antiviral Agents:  Antiretroviral Agents in Basic & Clinical Pharmacology 13e (Katzung BG Trevor AJ, eds) 2015, online edition.

  4. AIDSinfo:  Guidelines for the Use of Antriretroviral Agents in HIV-1-Infected Adults and Adolescents https://aidsinfo.nih.gov/guidelines (2015)

  5. Tsibris AMN Hirsch MS Chapter 130 Antiretroviral Therapy for Human Immunodeficiency Virus Infection in Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8e (Bennett JE Bolin R Blaser, eds) Elsevier, Inc/Saunders 2015, online version.

  6. Woster PM Antiviral Agents and Protease Inhibitors.  Chapter 43  in Foye's Principles of Medicinal Chemistry, 6e Lemke TL; Williams DA, eds; Roche VF Zito SW, asst. eds), Lippincott Williams & Wilkins, a Wolters Kluwer business, 1219, 2008.

  7. Swaminathan J and MSD staff at the European Bioinformatics Institute  (http://www.ebi.ac.uk/) Renin:  molecular structure registered with 2rn code. https://commons.wikimedia.org/wiki/File:PDB_2ren_EBI.jpg

  8. Flexner C HIV-Protease Inhibitors The New England Journal of Medicine 338(18) 1281-1292, April 30, 1998. http://www.ncbi.nlm.nih.gov/pubmed/9562584

  9. Billah Z Drug Resistance in HIV Protease Mutant with Darunavir https://www.youtube.com/watch?v=ou7-b5WRVjM (Published May 21, 2014)

  10. Liu F Kovalevsky AY Tie Y Ghosh AK Harrison RW Weber IT Effect of flap mutations on structure of HIV-1 Protease and  inhibition by saquinavir and darunavir J. Mol. Biol 381:  102-115, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18597780 (second sourced from reference 9)

  11. Tie Y Boross PI Wang Y-F Gaddis L Hussain AK Leshchenko S Ghosh AK Louis JM Harrison RW Weber IT High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.  J. Mol. Biol. 338:  341-252, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15066436 (second sourced from reference 9).

  12. HIV-1 protease (https://en.wikipedia.org/wiki/HIV-1_protease);  Graphic contributed by  Boghog https://en.wikipedia.org/wiki/File:HIV_protease_1KJF.png

  13. Stellbrink JH Pulik P Szlvik J Murphy D Lazzarin A Portilla J Rinehart A Le Fevre E Fang A Valluri S Mukwaya G Heera J  Maraviroc (MVC) dosed once daily with darunavir/ritonavir (DRV/r) in a 2 drug-regimen compared to emtricitabing/tenofovir (TDF/FTC) with DRV/r; 48-week results from MODERN (Study A4001095). AIDS 2014; published July 29, 2014) https://www.youtube.com/watch?v=JMMqkXx4YrU

  14. Wensing AM Calvez V Gunthard JF Johnson VA Paredes R Pillay D Shafer RW Richman DD Special Contribution:  2014 Update of the Drug Resistance Multations in HIV-1 Topics in Antivral Medicine 22(3)  June/July 2014, https://www.iasusa.org/sites/default/files/tam/22-3-642.pdf

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.